Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 ras should replace metformin in the type 2 diabetes algorithm

Diabetes Care

Volumn 40, Issue 8, 2017, Pages 1121-1127

  Abdul Ghani, Muhammad ^a,b   DeFronzo, Ralph A ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HAMAD GENERAL HOSPITAL   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; METFORMIN;

AGONISTS; ALGORITHM; ANALYSIS; CARDIOVASCULAR DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ALGORITHMS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85028091683     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-2368     Document Type: Article

References (74)

1. DeFronzo RA. Banting Lecture. Fromthe triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
2. Inzucchi SE, Bergenstal RM, Buse JB, et al.Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
3. Garber AJ, Abrahamson MJ, Barzilay JI, et al.; American Association of Clinical Endocrinologists (AACE); American College of Endocrinology (ACE). Consensus statement of the American Association of Clinical Endocrinology and American College of Endocrinology on the comprehensive type 2 diabetes algorithm-2015 executive summary. Endocr Pract 2015;21:1403-1414
4. International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, Belgium, International Diabetes Federation, 2012, p. 44-46
5. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443
6. United Kingdom Prospective Diabetes Study (UKPDS). 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-88
7. Abdul-Ghani MA, Puckett C, Triplitt C, et al. Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results fromthe Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial. Diabetes Obes Metab 2015;17:268-275
8. Abdul-Ghani M, Mujahid O, Mujahid A, et al. Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plusmetformin: the QATAR Study. Diabetes Care 2017;40:325-331
9. Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl JMed 2016;375: 311-322
10. Marso SP, Bain SC, ConsoliA, et al.; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-1844
11. Abdul-GhaniMA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010;2010:476279
12. Groop LC, Widén E, Ferrannini E. Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods? Diabetologia 1993;36:1326-1331
13. Shalata A, Jazmawi W, Aslan O, et al. Early metabolic defects in Arab subjects with strong family history of type 2 diabetes. J Endocrinol Invest 2013;36:417-421
14. Reaven GM. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich) 2011; 13:238-243
15. Kashyap S, Belfort R, Gastaldelli A, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003;52:2461-2474
16. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014;383:1068-1083
17. Alejandro EU, Gregg B, Blandino-Rosano M, Cras-Méneur C, Bernal-Mizrachi E. Natural history of b-cell adaptation and failure in type 2 diabetes. Mol Aspects Med 2015;42:19-41
18. Halban PA, Polonsky KS, Bowden DW, et al. b-Cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care 2014;37:1751-1758
19. Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 1988;319:1500-1506
20. Ferrannini E, Gastaldelli A, Miyazaki Y, MatsudaM,Mari A, DeFronzo RA. b-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005;90:493-500
21. Ferrannini E,Mari A. b-Cell function in type 2 diabetes. Metabolism 2014;63:1217-1227
22. Polonsky KS. Lilly Lecture 1994. The b-cell in diabetes: from molecular genetics to clinical research. Diabetes 1995;44:705-717
23. Jornayvaz FR, Samuel VT, Shulman GI. The role of muscle insulin resistance in the pathogenesis of atherogenic dyslipidemia and nonalcoholic fatty liver disease associated with the metabolic syndrome. Annu Rev Nutr 2010;30:273-290
24. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011;95:875-892
25. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
26. Nauck MA, Meier JJ. The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions. Lancet Diabetes Endocrinol 2016;4:525-536
27. Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. Diabetes Care 2016;39:884-892
28. Matsuda M, DeFronzo RA, Glass L, et al. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals. Metabolism 2002;51:1111-1119
29. Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia 2007;50:797-805
30. Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol Rev 2015; 95:513-548
31. Gamble JM, Clarke A,Myers KJ, et al. Incretinbased medications for type 2 diabetes: an overview of reviews. Diabetes Obes Metab 2015;17: 649-658
32. UmapathysivamMM, LeeMY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes 2014; 63:785-790
33. Chang AM, Jakobsen G, Sturis J, et al. The GLP-1 derivative NN2211 restores b-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003;52:1786-1791
34. Kapitza C, Dahl K, Jacobsen JB, Axelsen MB, Flint A. The effects of semaglutide on b-cell function in subjects with type 2 diabetes (Abstract). Diabetes 2016;65(Suppl. 1):A262
35. Bunck MC, Cornér A, Eliasson B, et al. Effects of exenatide on measures of b-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2041-2047
36. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
37. DiamantM, Van Gaal L, Guerci B, et al. Exenatide onceweekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. Lancet Diabetes Endocrinol 2014;2:464-473
38. Eldor R, Daniele G, Huerta C, et al. Discordance between central (brain) and pancreatic action of exenatide in lean and obese subjects. Diabetes Care 2016;39:1804-1810
39. van Bloemendaal L, Ten Kulve JS, la Fleur SE, Ijzerman RG, Diamant M. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 2014;221:T1-T16
40. ArmstrongMJ, Hull D, Guo K, et al. Glucagonlike peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016;64:399-408
41. Cusi K. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 2016;59:1112-1120
42. Mann JF, Brown Frandsen K, Daniels G, et al. Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial (Abstract). J Am Soc Nephrol 2016;27(Abstract Edition):1B
43. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week doseranging studies. Diabetes Care 2016;39:198-205
44. DeFronzo RA, Buse JB, KimT, et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 2016;59:1645-1654
45. Sarwar N, Gao P, Seshasai SR, et al.; Emerging Risk Factors Collaboration. Diabetesmellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215-2222
46. Di Angelantonio E, Kaptoge S, Wormser D, et al.; Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality [published correction appears in JAMA 205;314:1179]. JAMA 2015;314:52-60
47. Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial InmacroVascular Events): a randomised controlled trial. Lancet 2005;366: 1279-1289
48. Kernan WN, Viscoli CM, Furie KL, et al.; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
49. Zinman B,Wanner C, Lachin JM, et al.; EMPAREG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
50. Wu JH, Foote C, Blomster J, et al. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adultswith type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2016;4:411-419
51. Simpson SH,Majumdar SR, Tsuyuki RT, Eurich DT, Johnson JA. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 2006;174:169-174
52. Evans JM, Ogston SA, Emslie-Smith A,Morris AD. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-936
53. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
54. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
55. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 Diabetes. N Engl J Med 2015;373:232-242
56. Gerstein HC, Bosch J, Dagenais GR, et al.; ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367:319-328
57. Verge D, López X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type2diabetes. CurrDiabetes Rev 2010;6:191-200
58. Koska J, Sands M, Burciu C, et al. Exenatide protects against glucose-and lipid-induced endothelial dysfunction: evidence for direct vasodilation effect of GLP-1 receptor agonists in humans. Diabetes 2015;64:2624-2635
59. Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 2013;17:819-837
60. Drucker DJ. The cardiovascular biology of glucagon-like peptide-1. CellMetab 2016;24:15-30
61. DeFronzo RA, Goodman AM; TheMulticenter Metformin Study Group. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:541-549
62. Cusi K,DeFronzoRA.Metformin: areviewof its metabolic effects. Diabetes Reviews 1998;6:89-131
63. Natali A, Ferrannini E. Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review. Diabetologia 2006;49:434-441
64. Jensen JB, Gormsen LC, Sundelin E, et al. Organ-specific uptake and elimination of metformin can be determined in vivo in mice and humans by PET-imaging using a novel 11C-metformin tracer (Abstract). Diabetes 2015;64(Suppl. 1):LB33
65. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
66. Hare KJ, Knop FK, Asmar M, et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009;94:4679-4687
67. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev 2016;32:776-790
68. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
69. Henry RR, Rosenstock J, Logan D, Alessi T, Luskey K, BaronMA. Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes. J Diabetes Complications 2014;28:393-398
70. Novo Nordisk A/S. Efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes (PIONEER 3). In: ClinicalTrials.gov [Internet]. Bethesda, MD, National Library of Medicine, 2017. Available from https://clinicaltrials.gov/ct2/show/NCT2607865. NLM Identifier: NCT02607865. Accessed 18 May 2017
71. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033-1046
72. Cusi K, Consoli A, DeFronzo A. Metabolic effects ofmetformin on glucose and lactatemetabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1996;81:4059-4067
73. DeFronzo RA, Barzilai N, Simonson DC.Mechanismofmetformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab 1991;73:1294-1301
74. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-506